Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

Radon, an odorless radioactive gas that seeps from soil into homes, is responsible for an estimated 21,000 lung cancer deaths each year in the United States. That figure, drawn from federal risk ...

The alternative medicine industry is expanding rapidly, fueled in large part by the surge of health-related content on social ...

Theralase Technologies (TSXV:TLT) has shown in pre-clinical data that its flagship Rutherrin, when activated by X-Ray, is ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Today, Kalei Martin shares her journey online to raise awareness about colorectal cancer, particularly in younger adults ...

Breakthrough immunotherapy trials are showing unprecedented responses in a subset of rectal cancer patients, hinting at a ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic ...

By the time symptoms appear, the opportunity for early intervention has often narrowed. Across all cancer types, when detected at stage 1 ( while still localized), the five-year survival rate exceeds ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...